We are live on
!
Find out more
EU
Emory University Portfolio holdings
AUM
$267M
1-Year Est. Return
48.26%
This Fund
S&P 500
This Quarter
Est. Return
+8.48%
1 Year Est. Return
+48.26%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$106M
AUM Growth
+$4.36M
(+4.3%)
Cap. Flow
-$1.35M
Cap. Flow
% of AUM
-1.28%
Top 10 Holdings %
Top 10 Hldgs %
48.69%
Holding
48
New
6
Increased
14
Reduced
19
Closed
7
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
BioCryst Pharmaceuticals
BCRX
|
+$2.61M |
| 2 |
ONC
BeOne Medicines Ltd
ONC
|
+$2.1M |
| 3 |
RARX
Ra Pharmaceuticals, Inc. Common Stock
RARX
|
+$1.98M |
| 4 |
FOMX
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
|
+$1.96M |
| 5 |
LEXEA
Liberty Expedia Holdings, Inc. Class A Common Stock
LEXEA
|
+$1.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Aclaris Therapeutics
ACRS
|
+$2.46M |
| 2 |
SIOX
Sio Gene Therapies Inc. Common Stock
SIOX
|
+$1.97M |
| 3 |
Nektar Therapeutics
NKTR
|
+$1.87M |
| 4 |
Allison Transmission
ALSN
|
+$1.77M |
| 5 |
TG Therapeutics
TGTX
|
+$1.76M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 38.5% |
| 2 | Financials | 35.38% |
| 3 | Technology | 6.18% |
| 4 | Energy | 4.96% |
| 5 | Consumer Discretionary | 4.67% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Willis Towers Watson
WTW
$27.7B
| $1.7M | 1.61% |
12,999
-179
| -1% | -$22.8K |
|
27
Microsoft
MSFT
$2.93T
| $1.7M | 1.6% |
25,745
-2,407
| -9% | -$154K |
|
|
LEXEA
28
DELISTED
Liberty Expedia Holdings, Inc. Class A Common Stock
LEXEA
| $1.66M | 1.57% |
+36,500
| New | +$1.6M |
|
29
Arch Capital
ACGL
$35.4B
| $1.66M | 1.57% |
52,488
-7,629
| -13% | -$233K |
|
|
LVNTA
30
DELISTED
Liberty Interactive Corporation Series A Liberty Ventures
LVNTA
| $1.65M | 1.56% |
37,098
-4,361
| -11% | -$187K |
|
|
WBC
31
DELISTED
WABCO HOLDINGS INC.
WBC
| $1.64M | 1.55% |
13,972
-1,755
| -11% | -$198K |
|
32
CBRE Group
CBRE
$41.3B
| $1.61M | 1.52% |
46,318
-10,447
| -18% | -$349K |
|
33
LPL Financial
LPLA
$26B
| $1.59M | 1.5% |
39,989
-3,120
| -7% | -$123K |
|
|
BHI
34
DELISTED
Baker Hughes
BHI
| $1.58M | 1.49% |
26,457
-177
| -0.7% | -$10.8K |
|
35
Kinder Morgan
KMI
$71.9B
| $1.57M | 1.48% |
72,189
-2,259
| -3% | -$49.4K |
|
36
Seagate
STX
$178B
| $1.56M | 1.47% |
34,005
-8,197
| -19% | -$364K |
|
37
Viasat
VSAT
$9.76B
| $1.55M | 1.46% |
24,253
+4,137
| +21% | +$271K |
|
|
ESRX
38
DELISTED
Express Scripts Holding Company
ESRX
| $1.54M | 1.45% |
23,368
+2,300
| +11% | +$158K |
|
39
Trinity Industries
TRN
$2.9B
| $1.54M | 1.45% |
+80,402
| New | +$1.58M |
|
40
Morgan Stanley
MS
$339B
| $1.53M | 1.45% |
35,782
-5,288
| -13% | -$235K |
|
|
FOMX
41
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
| $1.01M | 0.95% |
+203,519
| New | +$1.96M |
|
|
42
Aclaris Therapeutics
ACRS
$793M
| – | – |
-90,704
| Closed | -$2.46M |
|
|
43
Allison Transmission
ALSN
$9.42B
| – | – |
-52,527
| Closed | -$1.77M |
|
44
Antero Resources
AR
$10.4B
| – | – |
-64,415
| Closed | -$1.52M |
|
45
Cerus
CERS
$627M
| – | – |
-372,841
| Closed | -$1.62M |
|
|
46
Nektar Therapeutics
NKTR
$2.31B
| – | – |
-10,171
| Closed | -$1.87M |
|
|
47
TG Therapeutics
TGTX
$8.4B
| – | – |
-379,499
| Closed | -$1.76M |
|
|
SIOX
48
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
| – | – |
-19,854
| Closed | -$1.97M |
|
Similar funds
CFG
PC
ALC
TWM
IP
SP
EAIC
STB
Emory University's Q1 2017 Portfolio in Review
As of Q1 2017, Emory University held 48 positions worth $106M, up 4.3% from $102M the previous quarter. Its ten largest holdings account for 49% of the portfolio.
Emory University's Q1 2017 filing shows 6 new, 14 increased, 19 reduced and 7 closed positions. Its largest new stake was BioCryst Pharmaceuticals: 375,348 shares worth $3.15M. The largest sale was Aclaris Therapeutics, an estimated $2.46M.
By sector, the portfolio is most concentrated in Healthcare at 39% of assets, up from 37% a quarter earlier, followed by Financials and Technology.
- Emory University's largest Q1 2017 buy was BioCryst Pharmaceuticals: 375,348 shares worth $3.15M.
- Emory University added most to Bellicum Pharmaceuticals, Inc. in Q1 2017, an estimated $909K increase.
- Emory University's biggest Q1 2017 reduction was Acadia Pharmaceuticals, cutting an estimated $705K.
- Emory University fully exited Aclaris Therapeutics in Q1 2017, selling an estimated $2.46M.
- Emory University's ten largest holdings make up 49% of its $106M portfolio in Q1 2017.
- Emory University opened 6 new positions and closed 7 in Q1 2017.
- Emory University's portfolio value rose 4.3% quarter-over-quarter to $106M.
Based on Emory University's 13F filing for Q1 2017, filed 11 May 2017.